Cerevel Therapeutics Holdings Receivables

Cerevel Therapeutics Holdings (CERE) currently reports a receivables of $5M as of March 2024. That compares with $3.2M in the prior-year period — up 55.0% year over year. Use the charts on this page to explore Cerevel Therapeutics Holdings's receivables history and peer comparisons.

Cerevel Therapeutics Holdings's receivables increased from $3.2M to $5M — a 55.0% year-over-year increase (period ending March 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Cerevel Therapeutics Holdings reported $5M in receivables as of March 2024. That compares with $3.2M in the prior-year period — up 55.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $5M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Cerevel Therapeutics Holdings, and consider following CERE for alerts when major investors trade the stock.

Cerevel Therapeutics Holdings is classified in the Healthcare sector. On receivables, it currently shows $5M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CERE with unrelated industries.